[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patellofemoral-osteoarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patellofemoral-osteoarthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,72,98,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100528653","phase-2-treatment-of-patellofemoral-osteoarthritis-with-engineered-cartilage-100528653",false,"NCT06163573","Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.","Treatment of Patellofemoral Osteoarthritis With Nasal Chondrocyte-based Engineered Cartilage Implantation in a Randomized, Controlled, Multi-center Phase II Clinical Trial","Inclusion Criteria:\n\n* Patient age is ≥18 and ≤ 65 years at time of screening.\n* Symptomatic PFOA grade 1-3 according to Iwano Classification\n* Chondropathy Grade 3-4 according to ICRS classification of the patella, trochlea femoris or both\n* Baseline score of \\\u003C60 on the KOOS Pain subjective knee evaluation.\n* Free range of motion of the affected knee joint or ≤ 5° of extension loss and minimum 125° flexion.\n* Patient is willing and able to give written informed consent to participate in the study and to comply with all study requirements, including attending all follow-up visits and assessments and to complete postoperative rehabilitation regimen.\n* Minimum values for women: Haemoglobin 120g\u002Fl, Platelets 150G\u002Fl, INR\\\u003C1.3\n* Minimum values for men: Haemoglobin 140g\u002Fl, Platelets 150G\u002Fl, INR\\\u003C1.3\n* Non-surgical standard of care options except for PRP have been exhausted.\n\nExclusion Criteria:\n\n* Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol or in a dependency or employment with the sponsor.\n* Patient is unable to understand the patient information\n* Patient is unable to undergo magnetic resonance imaging (MRI)\n* Prior surgical treatment of the target knee within 12 months (Note: prior diagnostic arthroscopy with debridement and lavage are acceptable within 12 months).\n* Radiologically apparent degenerative joint disease of the tibiofemoral joint as determined by X-ray (Kellgren and Lawrence grade \\> 2) or MRI or pain in the tibiofemoral joint as assessed by clinical examination\n* Patient has excessive varus or valgus deformity (\\>5°)\n* Patient had a patellar dislocation in the afflicted knee in the last 2 years.\n* Patient has a symptomatic meniscus lesion (or removal exceeding ½), as indicated by clinical examination (joint line tenderness and McMurray test positive) and MRI.\n* Patient has a body mass index (BMI) \\>35 kg\u002Fm2.\n* Patient has chronic rheumatoid arthritis, and\u002For infectious arthritis\n* Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee.\n* Patient has a known immunological suppressive disorder or is taking immunosuppressives.\n* Patient had any intra-articular injections into the affected knee within the last 3 months before baseline visit\n* Instability of anterior, posterior collateral ligaments\n* The patient has a HIV\u002FAIDS infection. (regulatory requirement)\n* The patient has an acute Treponema pallidum (syphilis) infection. (regulatory requirement)\n* The patient has an active hepatitis B or C infection with verified antigens. Patients with a cured hepatitis B or C infection and\u002For verified antibodies are not excluded. (regulatory requirement)\n* Patient is pregnant, breast feeding or anticipates becoming pregnant within 24 months after surgery.\n* Patient is currently participating or has participated in any other clinical study within 3 months prior to the screening visit.\n* Patient has known current or recent history of illicit drug or alcohol abuse or dependence defined as the continued use of alcohol or drugs despite the development of social, legal or health problems.\n* Patient has any other condition, which, in the opinion of the investigator, would make the patient unsuitable for the study.\n* Any known allergies, especially for porcine collagen, penicillin or streptomycin (manufacturing)\n* patients with increased anesthesiological and surgical risks (e.g. known or predicted difficult airway, myocardial infarction \\\u003C60 days prior to surgery)\n* patients with increased bleeding risk (e.g. coagulopathies)\n* patients on anticoagulants whose anticoagulant therapy cannot be interrupted as appropriate to the given agent(s) and underlying condition\n* Patients with any active infections","ALL","18 Years","65 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage (N-TEC), in comparison with a standard therapy using platelet rich plasma injections.\n\nThe engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I\u002FIII membrane.",[27],"Patellofemoral Osteoarthritis",[29,30,31,32],"Nasal chondrocytes","Tissue engineering","Knee cartilage","Patellofemoral osteoarthritis","RECRUITING","2026-06-10",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":37},"2024-06-06",{"date":41,"type":21},"2029-09",{"name":43,"class":44},"University Hospital, Basel, Switzerland","OTHER",9,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100639070","fdg-petmri-imaging-of-patellofemoral-joint-osteoarthritis-100639070","NCT07625150","FDG PET\u002FMRI Imaging of Patellofemoral Joint Osteoarthritis","Understanding Painful Inflammation in Patellofemoral Joint OA Using [18F] FDG","FDG-PFJOA","Inclusion Criteria:\n\n* Adult with the capacity to give informed consent\n* Ability to perform 25 single-leg squats\n* No traumatic knee injuries\u002Fsurgeries since last visit for the parent study (IRB #21-34763)\n* No investigational drugs since last visit for the parent study (IRB #21-34763)\n* No contraindications to MRI or PET tracer since last visit for the parent study (IRB #21-34763)\n* Not taking steroid injections\n* Not pregnant\n* Additional inclusion criteria for healthy volunteers: Minimal pain (VAS=0-1) during a series of 25 single-leg squats on one or both legs\n\nExclusion Criteria:\n\n* Inability to consent for themselves\n* Inability to perform 25 single-leg squats with the study leg\n* New traumatic knee injuries\u002Fsurgeries since last visit for the parent study (IRB #21-34763)\n* Taking investigational drugs since last visit for the parent study (IRB #21-34763)\n* New contraindications to MRI or PET tracer since last visit for the parent study (IRB #21-34763)\n* Taking steroid injections\n* Pregnant\n* Diabetic\n* Additional exclusion criteria for healthy volunteers: VAS of 2 or greater during a series of 25 single-leg squats on both legs",{"count":55,"type":21},50,"OBSERVATIONAL","This project aims to develop an \\[18F\\] fluorodeoxyglucose (FDG) positron emission tomography (PET) \u002F magnetic resonance imaging (MRI) method to locate the painful inflammation in PFJ OA associated with joint loading. \\[18F\\] FDG PET\u002FMRI is an emerging pain imaging approach with enhanced sensitivity to painful hypermetabolic inflammation through evaluation of intracellular glucose utilization rate via (\\[18F\\]FDG PET) and fine anatomy details (MRI). The investigative group has shown its promise in revealing previously unidentified or unspecified pain generators in various musculoskeletal pain conditions. The investigators have also demonstrated the feasibility of visualizing the structural changes between unloaded and loaded knee joints with MRI, which can be easily adopted in the current PET\u002FMRI setting. The main challenge in the proposed \\[18F\\]FDG PET\u002FMRI approach is to differentiate the normal uptake of FDG for metabolic changes by weight-bearing from abnormal changes indicating eventual pain aggravation by weight-bearing and knee-flexion. The investigators have garnered the following two aims to validate the proposed method by comparing unloaded and loaded knee imaging results between PFJ OA pain patients and asymptomatic, matched controls.",[27,59,60,61],"Knee Osteoarthritis","Knee Pain","Inflamation","2026-06-01",{"date":64,"type":37},"2026-06-04",{"date":66,"type":37},"2025-02-19",{"date":68,"type":21},"2028-02",{"name":70,"class":44},"University of California, San Francisco",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100560395","phase-2-implantation-of-engineered-cartilage-grafts-for-treatment-of-patellofemoral-osteoarthritis-versus-surgical-comparators-100560395","NCT06576583","Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.","Randomized, Controlled, Multi-center Phase II Clinical Trial for the Treatment of Patellofemoral Osteoarthritis With Nasal Chondrocyte-based Tissue Engineered Cartilage Implantation vs Current Standard of Care","ENCANTO","Inclusion Criteria:\n\n* Patient age is ≥18 and ≤ 70 years at time of screening.\n* Symptomatic PFOA grade 1-4 according to Iwano Classification\n* Chondropathy Grade 3-4 according to ICRS classification of the patella, trochlea femoris or both\n* Baseline score of \\\u003C75 on the KOOS-5 subjective knee evaluation.\n* Free range of motion of the affected knee joint or ≤ 5° of extension loss and minimum 125° flexion.\n* Patient is willing and able to give written informed consent to participate in the study and to comply with all study requirements, including attending all follow-up visits and assessments and to complete postoperative rehabilitation regimen.\n* Minimum values for women: Haemoglobin 120g\u002Fl, Platelets 150G\u002Fl, INR\\\u003C1.3\n* Minimum values for men: Haemoglobin 140g\u002Fl, Platelets 150G\u002Fl, INR\\\u003C1.3\n* Patients have failed to demonstrate adequate response to non-pharmacological interventions (e.g. structured land-based exercise programs) and pharmacological first-line treatment such as topical NSAIDs\n\nExclusion Criteria:\n\n* Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol or in a dependency or employment with the sponsor.\n* Patient is unwilling, unable or lacking the capacity to provide informed consent\n* Patient is unable to undergo magnetic resonance imaging (MRI)\n* Prior surgical treatment of the target knee within 12 months (Note: prior diagnostic arthroscopy with debridement and lavage are acceptable within 12 months).\n* Radiologically apparent degenerative joint disease of the tibiofemoral joint as determined by X-ray (Kellgren and Lawrence grade \\> 2) or MRI or pain in the tibiofemoral joint as assessed by clinical examination\n* Patient has excessive varus or valgus deformity (\\>5°), unless corrected during implantation\n* Patient has a symptomatic meniscus lesion (or removal exceeding ½), as indicated by clinical examination (joint line tenderness and McMurray test positive) and MRI.\n* Patient has a body mass index (BMI) \\>35 kg\u002Fm2.\n* Patient has chronic rheumatoid arthritis, and\u002For infectious arthritis\n* Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee.\n* Patient has a known immunological suppressive disorder or is taking systemic immunosuppressives.\n* Patient had any intra-articular injections into the affected knee within the last 3 months before baseline visit\n* Instability of anterior, posterior and\u002For collateral ligaments\n* The patient has a HIV\u002FAIDS infection. (regulatory requirement)\n* The patient has an acute Treponema pallidum (syphilis) infection. (regulatory requirement)\n* The patient has an active hepatitis B or C infection with verified antigens. Patients with a cured hepatitis B or C infection and\u002For verified antibodies are not excluded. (regulatory requirement)\n* Patient is pregnant, breast feeding or anticipates becoming pregnant within 24 months after surgery.\n* Patient is currently participating or has participated in any other clinical study within 3 months prior to the screening visit.\n* Patient has known current or recent history of illicit drug or alcohol abuse or dependence defined as the continued use of alcohol or drugs despite the development of social, legal or health problems.\n* Patient has any other condition, which, in the opinion of the investigator, would make the patient unsuitable for the study.\n* Known allergies for porcine collagen (scaffold), penicillin or streptomycin (manufacturing)\n* Nail-patella syndrome\n* Patients who will likely benefit from conservative therapy, such as physiotherapy, medical training therapy and pain medication\n* Patients with increased anesthesiological and surgical risks (e.g. known or predicted difficult airway, myocardial infarction \\\u003C60 days prior to surgery)\n* Patients with increased bleeding risk (e.g. coagulopathies)\n* Patients on anticoagulants whose anticoagulant therapy cannot be interrupted as appropriate to the given agent(s) and underlying condition\n* Patients with any active infections","70 Years",{"count":82,"type":21},150,[24],"ENCANTO is a randomized, controlled, multi-center phase II clinical trial for the treatment of patellofemoral osteoarthritis (PFOA) with an Advanced Therapy Medicinal Product (ATMP), nasal chondrocyte-based tissue engineered cartilage (N-TEC) implantation in comparison with current standard of care depending on the stage of osteoarthritis. The goal of this phase II trial is to evaluate the efficacy of N-TEC treatment in comparison to an active comparator Autologous Matrix Induced Chondrogenesis (AMIC) for early stage PFOA or patellofemoral arthroplasty (PFA) for late stage PFOA.\n\nThe N-TEC engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I\u002FIII membrane.",[27],[29,30,31,32,87,88],"Autologous Matrix Induced Chondrogenesis (AMIC)","Patellofemoral arthroplasty (PFA)","2026-03-19",{"date":91,"type":37},"2026-03-24",{"date":93,"type":37},"2025-07-15",{"date":95,"type":21},"2030-01",{"name":43,"class":44},11,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":18,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":5},"100548615","evaluation-of-the-patellar-lift-system-for-subjects-with-patellofemoral-cartilage-degeneration-100548615","NCT06423300","Evaluation of the Patellar LIFT System for Subjects With Patellofemoral Cartilage Degeneration","PELICAN","Inclusion Criteria:\n\n1. Patients age 22 to 65 years at time of screening\n2. Anterior knee pain due to patellofemoral cartilage degeneration (PCD) with an Modified Outerbridge score of ≥3 as assessed by an MRI on the study knee\n3. Body Mass Index (BMI) of ≤ 35\n4. Weight \\\u003C 300 lbs\n5. Anterior Knee Pain Score (AKPS) of ≤ 70 (0-100 scale)\n6. Visual Analog Score (VAS) of ≥ 40 (0-100 scale)\n7. Failure of at least 6 months of non-surgical treatment defined as at least one of the treatments (e.g. rest, bracing, physical therapy, targeted exercise, use of NSAIDs, activity level reduction or Confidential ZKR Orthopedics, CIP 0001 Page 11 of 55 Protocol Version: 1.0, 04JAN2024 modification, etc.) per AAOS Treatment of Osteoarthritis of the Knee; Evidence based guideline 3rd Edition 2021\n\nExclusion Criteria:\n\n1. PCD with an Modified Outerbridge Score of 2 or less at the study knee\n2. Clinical symptoms of the contralateral knee that preclude activities of daily living, stair climbing, stair descending, or require the use of an assist device\n3. History of patella dislocation or instability\n4. Patella alta or patella baja\n5. Known TT-TG distance \\>20mm\n6. Patients requiring simultaneous cartilage grafting procedure, cartilage transplantation, or bone marrow stimulation\n7. Previous repair of a torn patellar tendon\n8. Prior TTO procedure or knee joint replacement (total or partial) of the study knee\n9. Joint modifying surgery (e.g., ligament reconstruction, meniscus repair, cartilage transplantation, microfracture, etc.) in the study knee within 6 months prior to planned index procedure date\n10. Arthroscopic surgeries in the study knee for joint lavage, meniscectomy, chondral debridement, and loose body removal within 3 months prior to planned index procedure\n11. Active infection, sepsis, osteomyelitis or history of septic arthritis in any joint\n12. Rheumatoid arthritis, other forms of inflammatory joint disease or autoimmune disorder\n13. History of avascular necrosis of any bone\n14. History of symptomatic patellar tendonitis of intrasubstance tear\n15. Insufficiency of the cruciate, collateral ligaments, or tendon which would preclude stability of the LIFT System\n16. Pathologic ligamentous injury (Lachman \\> 1) or meniscus tearing\n17. Clinical symptoms of the femoral-tibial joint of the study knee that preclude activities of daily living, stair climbing, stair descending, or requires the use of an assist device\n18. Evidence (MRI, arthroscopy, etc.) of Modified Outerbridge Grade 4 degenerative arthritis in the femoral-tibial joint of the study knee that potentially explains patient symptoms","22 Years",{"count":107,"type":21},245,[109],"NA","The PELICAN study is a prospective, non randomized, dual arm, multi-center clinical study comparing clinical outcomes of subjects treated with the LIFT Implant System to subjects treated with Tibial Tubercle Osteotomy (TTO).",[27],"2025-12-04",{"date":114,"type":37},"2025-12-11",{"date":116,"type":37},"2024-06-19",{"date":118,"type":21},"2031-09",{"name":120,"class":121},"ZKR Orthopedics Inc","INDUSTRY",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":18,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":71},"100434503","prp-versus-ha-in-osteoarthritis-of-the-patellofemoral-joint-100434503","NCT04937998","PRP Versus HA IN OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT","THE USE OF FRESH PRP VS HA IN THE TREATMENT OF OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age between 30 and 65;\n2. Signs and symptoms of isolated patellofemoral osteoarthritis present in one or both knees;\n3. Radiographic signs of isolated patellofemoral osteoarthritis (according to Iwano et al stage 1-3 classification) or chondropathy (assessed on MRI) with K-L grade of the other compartments ≤ 2. \\[PMID: 2302884 - PMID: 27979409\\] ;\n4. Hemoglobin \\> 11 g\u002Fdl; Platelet count \\> 150,000 plt\u002Fmm3 (Recently performed CBC exam);\n5. No clinically significant electrocardiographic alterations (Recently performed ECG).\n6. Ability and consent of patients to actively participate in clinical follow-up;\n7. Signature of informed consent.\n\nExclusion Criteria:\n\n1. Patients unable to express consent;\n2. Patients who have undergone intra-articular infiltration of another substance within the previous 6 months;\n3. Patients undergoing knee surgery within the previous 12 months;\n4. Patients with malignant neoplasms;\n5. Patients with rheumatic diseases;\n6. Patients with diabetes;\n7. Patients with hematologic diseases (coagulopathies);\n8. Patients on anticoagulant-antiaggregant therapy;\n9. Patients with thyroid metabolic disorders;\n10. Patients abusing alcoholic beverages, drugs or medications;\n11. Body Mass Index \\> 35;\n12. Patients who have taken NSAIDs in the 3 days prior to blood draw;\n13. Patients with cardiovascular disease for which a 60 mL blood draw would be contraindicated;\n14. Patients with a recently performed blood test with Hb\\\u003C 11 g\u002Fdl and Platelets \\\u003C 150,000 plt\u002Fmm3.\n15. Previous treatment of patellar dislocation\n16. Iwano score of grade 4.","30 Years",{"count":131,"type":21},166,[109],"The aim of the study is to compare the 12-month clinical outcomes of patients with patellofemoral osteoarthritis undergoing infiltrative treatment with fresh PRP and HA",[27],[136,137,138,139,140,141,142,143,144,145],"PRP","HA","Osteoarthritis","Autologous PRP","PRP injection","HA injection","injection treatment","Randomized controlled trial","Hyaluronic Acid","Platelet rich plasma","2025-12-03",{"date":112,"type":37},{"date":149,"type":37},"2022-10-26",{"date":151,"type":21},"2026-09",{"name":153,"class":44},"Istituto Ortopedico Rizzoli"]